Company Profile
Prime Medicine Stock Price, News & Analysis
- Ticker:
- PRME
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
3.01 USD (+2.03%)
Close
Last updated: July 27, 2026
580M USD
Market cap
Why the stock is moving
As of Jul 27, 2026, PRME closed up 2.03% at $3.01. No new same-company headline was identified in the current news window.
Company overview
Business overview
Prime Medicine is a gene-editing company focused on prime-editing technology for a broad set of genetic diseases. The platform aims to expand the precision and flexibility of genome editing.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Prime Medicine sits in advanced gene-editing biotechnology.
Business Model Characteristics
Its value is tied to platform validation, early clinical data, and the long-term ability to edit genes with fewer constraints than older tools.
Position Within the Biotechnology Landscape
Prime Medicine is a platform editing name with high upside if the science validates, but it remains deeply tied to early-stage milestones.
Future catalysts
Prime Medicine still has the most obvious catalysts in Wilson disease, AATD, and CGD. The IND and CTA filing plans for the Wilson disease and AATD programs, plus the FDA work around PM359, are the pieces that make the next few quarters feel real instead of purely platform-driven.
Recent news
The five most recent related feed items are shown below in reverse chronological order.
- 01
CLEAR To Announce Second Quarter 2026 Financial Results On August 5, 2026
YOU · Source: Clear Secure Inc
- 02
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NTLA · Source: Intellia
- 03
- 04
CLEAR to Strengthen Caller Verification in Contact Centers with AWS
YOU · Source: Clear Secure Inc
- 05
CLEAR Launches at Indianapolis International Airport
YOU · Source: Clear Secure Inc
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Prime Medicine (PRME)?
Prime Medicine (PRME) most recently closed at 3.01 USD, a +2.03% move versus the previous session.
What is the market cap of Prime Medicine (PRME)?
Prime Medicine currently has a market capitalization of 580M USD on BioPharmSignal.
What does Prime Medicine do?
Prime Medicine is a gene-editing company focused on prime-editing technology for a broad set of genetic diseases. The platform aims to expand the precision and flexibility of genome editing.
On which exchange is PRME stock listed?
Prime Medicine (PRME) is associated with NASDAQ, United States, Biopharma.
What is Prime?
Prime Medicine still has the most obvious catalysts in Wilson disease, AATD, and CGD.
Which conditions is Prime Medicine targeting with Prime?
Prime Medicine is associated with genetic disease based on its company overview and current catalyst commentary.
How does Prime Medicine describe recent progress with Prime?
Prime Medicine still has the most obvious catalysts in Wilson disease, AATD, and CGD.
What is Medicine?
Prime Medicine is a gene-editing company focused on prime-editing technology for a broad set of genetic diseases.